Ocean Biomedical, Inc. (OCEA): Nasdaq/NYSE listing notice — Ocean Biomedical receives Nasdaq delisting notice, plans to appeal; expands into energy and crypto

Ocean Biomedical, Inc.

Nasdaq determined OCEA common stock will be delisted and trading suspended effective April 24, 2025.
Company intends to appeal the delisting determination within 15 days but warns no guarantee of success.
Director Jake Kurtis resigned immediately on April 22, 2025 to pursue other interests.
Strategic expansion into power infrastructure and cryptocurrency treasury (Bitcoin and Solana) announced.
No specific financial commitments, project sizes, or capital sources disclosed for the new sectors.

item 3.01 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jake Kurtis

Director

OCEA · Ocean Biomedical, Inc.

Effective: 2025-04-22
Filed: April 23, 2025, 7:59 PM ET

On April 22, 2025, Jake Kurtis notified the Company of his immediate resignation as a director of the Company to pursue other interests.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Ocean Biomedical, Inc. received a nasdaq delisting notice notice regarding other.

Exchange: nasdaq
Notice: delisting notice

Exact text from the filing

April 22, 2025, Ocean Biomedical, Inc. received a letter from Nasdaq determining that OCEA’s common stock will be delisted from Nasdaq and that trading in its securities will be suspended effective upon the open of business on April 24, 2025. The letter also stated that Nasdaq intends to complete delisting by filing a Form 25 Notification of Delisting with the SEC after applicable appeal periods have lapsed. Pursuant to Nasdaq listing rules, the Company has the right to appeal Nasdaq’s delisting determination within 15 days of the date of the letter. The Company intends to file its appeal fort

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Jake Kurtis resigned as Director at Ocean Biomedical, Inc..

Action: resigned
Role: Director

Exact text from the filing

On April 22, 2025, Jake Kurtis notified the Company of his immediate resignation as a director of the Company to pursue other interests.

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Ocean Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-005788

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.